What is the pyrido[2,3-d]pyrimidine scaffold of palbociclib (C24H29N7O2; MW ~447.54 g/mol; CAS 571190-30-2; PD 0332991), how does it achieve CDK4 IC50 ~11 nM / CDK6 IC50 ~16 nM selectivity as a serine/threonine kinase inhibitor, and why does the cell cycle kinase class represent a fundamentally new OEL hazard category absent from all prior 24 mechanism classes in the Glyphward portfolio?

Palbociclib (Ibrance; CAS 571190-30-2; C24H29N7O2; MW ~447.54 g/mol; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one; PD 0332991 [Pfizer internal designation]; reversible ATP-competitive; CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM; CDK1 IC50 >4,000 nM [>360-fold CDK1-sparing]; CDK2 IC50 ~150 nM [~14-fold]; CDK5 IC50 >4,000 nM) is the TWENTY-FIFTH mechanism class in the 552-attack Glyphward adversarial portfolio and the FIRST CDK4/6 inhibitor ever approved in history (NDA 207103; February 3 2015). SCAFFOLD ARCHITECTURE: The pyrido[2,3-d]pyrimidine core is a bicyclic heteroaromatic ring system fusing a pyrimidine at positions 2 and 3 with a pyridine at positions [2,3-d] (IUPAC nomenclature: 1,8-naphthyridine variant). This is a FIRST in the Glyphward portfolio: all 24 prior mechanism classes used primarily pyrimidine-based, purine-based, or pyrrolo/thieno/quinazoline scaffolds; the pyrido[2,3-d]pyrimidine provides a larger bicyclic surface for hinge region contacts and a unique spatial geometry relative to the CDK4/CDK6 ATP-binding cleft. STRUCTURAL DETERMINANTS OF CDK4/6 SELECTIVITY: (1) The 8-cyclopentyl N-substituent occupies the hydrophobic pocket on the N-terminal lobe of CDK4 and CDK6 near the P-loop — this bulky alicyclic group is size-complementary to the CDK4/CDK6 hydrophobic pocket but sterically penalized in CDK2 and CDK1 (which have smaller P-loop pockets). (2) The 5-methyl and 6-acetyl groups fine-tune the geometry of the pyrido[2,3-d]pyrimidine to maximize contact area with Leu16 (CDK4) and Lys35 (CDK6) hinge residues. (3) The 2-amino-[5-(piperazin-1-yl)pyridin-2-yl] arm provides two canonical ATP-hinge backbone hydrogen bonds (to Val96-C=O and Leu18-NH in CDK4; to Val101-C=O and Leu23-NH in CDK6) plus the piperazinyl solvent-exposed amine improves aqueous solubility without adding hinge constraint. SERINE/THREONINE VS TYROSINE KINASE DISTINCTION: The prior 24 Glyphward mechanism classes were dominated by tyrosine kinases (ABL, EGFR, ALK, ROS1, VEGFR, KIT, PDGFR, BTK, MET, HER2, FLT3, BCR-ABL, SRC, FGFR, JAK — which are receptor or cytoplasmic tyrosine kinases) with BRAF/MEK/mTOR as serine/threonine kinases and PARP/KRAS as non-kinases. CDK4/6 are serine/threonine kinases with a fundamentally DIFFERENT cellular function: they are CELL CYCLE ENGINES rather than signal transduction amplifiers. CDK4/6 do not amplify extracellular ligand signals through cytoplasmic cascades — they directly phosphorylate nuclear protein substrates (Rb; RB1) to control progression from G1 to S phase in the cell division cycle. This mechanistic distinction means CDK4/6 inhibitor OEL hazard is cell-cycle-centric rather than receptor-signal-centric. OEL NULL-RETURN FRAMEWORK FAILURE: No NIOSH document, ACGIH TLV, or OSHA standard discusses: (i) CDK4/6 cell cycle mechanism as an occupational health endpoint; (ii) CDK4 IC50 ~11 nM / CDK6 IC50 ~16 nM serine/threonine kinase potency relative to hematopoietic progenitor CDK4/CDK6 dependence; (iii) cyclin D regulatory subunit biology (CCND1 overexpression in HR+ breast cancer); (iv) pyrido[2,3-d]pyrimidine scaffold identity or its metabolic pathways; (v) CDK1-sparing selectivity (>4,000-fold) as a worker-protective property (it is not — wild-type CDK4/CDK6 in G1 progenitors are engaged at IC50 ~11-16 nM regardless of CCND1 amplification status); (vi) intermittent 3-weeks-on/1-week-off dosing schedule rationale (allows neutrophil recovery in patients; does NOT protect workers on continuous occupational exposure). All three EHS platforms at Pfizer Groton CT (Cority), Pfizer McPherson KS (VelocityEHS), and MSKCC New York NY (EHS Insight) return null for CAS 571190-30-2.

What is the cyclin D–CDK4/6–Rb–E2F cell cycle checkpoint mechanism, why do HR+/HER2- breast cancer cells depend on CDK4/6 for proliferation (CCND1 chromosome 11q13), how does CDK4/6 inhibitor-associated neutropenia (Grade 3-4 ~66% in PALOMA-2) arise from wild-type CDK4/6 in hematopoietic progenitors, and why does RB1 loss create primary resistance?

CDK4/6–Rb–E2F CELL CYCLE CHECKPOINT BIOLOGY: The G1/S restriction checkpoint is the primary go/no-go control point of the mammalian cell cycle. In G1, the retinoblastoma protein (Rb; encoded by RB1; Ser807, Ser811, Thr821, Thr826 phosphorylation sites; ~110 kDa; chromosome 13q14) exists in its hypophosphorylated (active growth-suppressor) state — in this state Rb directly binds and sequesters E2F transcription factors (E2F1, E2F2, E2F3) in inactive repressor complexes. CDK4/CDK6, when activated by cyclin D regulatory subunits (cyclin D1 [CCND1], D2 [CCND2], D3 [CCND3]), phosphorylate Rb sequentially at these serine/threonine sites. Partially phosphorylated Rb weakens E2F binding; fully hyperphosphorylated Rb releases E2F factors, which then transactivate S-phase genes required for DNA replication: CDC6, MCM2-7 (replication licensing), RRM2 (dNTP synthesis), DHFR (folate metabolism), CCNE1 (cyclin E — for CDK2 activation in late G1/S transition). The sequence: mitogen signal (e.g., ER signaling → CCND1 transcription) → cyclin D1 accumulation → cyclin D1-CDK4 complex formation → CDK4 activated → Rb phosphorylation → E2F release → S-phase gene activation → DNA replication begins. Palbociclib competitively blocks ATP binding at CDK4 (IC50 ~11 nM) and CDK6 (IC50 ~16 nM) active sites → CDK4/6 cannot phosphorylate Rb → Rb remains hypophosphorylated → E2F factors remain sequestered → S-phase gene transactivation blocked → G1 cell cycle arrest. CYCLIN D1 DEPENDENCE AND HR+ BREAST CANCER SELECTIVITY: Estrogen receptor (ER) signaling is the primary driver of CCND1 transcription in HR+ breast cancer. ER binds estrogen response elements (EREs) in the CCND1 promoter, directly inducing cyclin D1 protein expression. Simultaneously, ER-driven PIK3CA → AKT signaling stabilizes cyclin D1 protein (phosphorylation at Thr286 → inhibition of GSK-3β-mediated proteasomal degradation). In HR+/HER2- breast cancers, ~85% of proliferative signaling routes through the ER → cyclin D1 → CDK4/6 → Rb axis. Additionally, CCND1 is amplified at chromosome 11q13 in ~15% of HR+/HER2- breast cancers, further driving CDK4/6 activity. HER2-amplified and TNBC cells rely less on CCND1-CDK4/CDK6 for proliferation (cyclin E-CDK2 or alternative pathways are dominant), explaining CDK4/6 inhibitor selectivity for HR+ disease. GRADE 3-4 NEUTROPENIA (~66%) DLT MECHANISM: Grade 3-4 neutropenia (ANC <1,000 cells/μL) is the primary dose-limiting toxicity of palbociclib in PALOMA-2 (66.4% Grade 3-4 palbociclib+letrozole vs 1.4% letrozole alone), but the mechanism is DISTINCT from chemotherapy neutropenia. Chemotherapy (cytarabine, doxorubicin) kills all rapidly dividing cells via direct DNA alkylation, strand breakage, or topoisomerase inhibition — cytotoxic, febrile neutropenia frequent (~15-30%), stem cell pool damage. CDK4/6 inhibitor neutropenia is CYTOSTATIC, not cytotoxic: palbociclib arrests hematopoietic progenitor cells (HSCs, CMPs, GMPs — which express CDK4 and CDK6 with cyclin D3 [CCND3] as the dominant D-type cyclin in hematopoietic cells) in G1 phase. The CDK4/CDK6-dependent G1 arrest in hematopoietic progenitors slows granulopoiesis → decreased neutrophil output from bone marrow → ANC nadir typically at days 14-21 of the 21-day on-treatment period → recovery during the 7-day off-treatment week. CRITICAL DISTINCTION: febrile neutropenia is uncommon in CDK4/6 inhibitor-associated neutropenia (~2% in PALOMA-2) because the mechanism is reversible cytostasis (progenitor cells remain viable, arrest is reversible on drug washout) rather than cytotoxic kill. Neutrophil reserve in mature granulocyte compartment persists. G-CSF (filgrastim) is NOT recommended as primary prophylaxis in PALOMA-2. Dose interruption (hold until ANC ≥1,000) + dose reduction (from 125 to 100 to 75 mg) manages most Grade 3-4 neutropenia events. For WORKERS at Pfizer Groton CT, Pfizer McPherson KS, and MSKCC: wild-type CDK4/CDK6 in hematopoietic progenitors is pharmacologically identical to patient CDK4/CDK6 — there is no therapeutic index. Occupational CDK4/6 inhibition via inhalation or dermal absorption → same hematopoietic G1 arrest → potential neutropenia — with NO monitoring framework in Cority, VelocityEHS, or EHS Insight. RB1 LOSS AND PRIMARY RESISTANCE: RB1 biallelic loss or truncating mutation — occurring in ~5-10% of HR+/HER2- breast cancers (more common in HER2+ [~10-20%] and TNBC [~30%]) — is the primary mechanism of intrinsic resistance to CDK4/6 inhibitors. Without intact Rb protein, palbociclib has no molecular substrate to maintain in the hypophosphorylated state: E2F factors are constitutively released regardless of CDK4/6 activity. Cyclin E1 (CCNE1) amplification (chromosome 19q12) at high amplitude provides an alternative CDK2-driven pathway to S-phase entry that bypasses CDK4/6 dependence — another primary resistance mechanism. ESR1 mutations (D538G, Y537S, Y537N — acquired endocrine resistance mutations) alter ER ligand-binding domain conformation, enabling ligand-independent ER activity, but ESR1-mutant ER retains transcriptional activity and can continue to drive CCND1 expression → ESR1 mutations confer endocrine resistance but NOT CDK4/6 inhibitor resistance (explaining PALOMA-3 activity in endocrine-refractory patients on fulvestrant). CDK4/6 acquired resistance includes CDK4/6 amplification (rare; <5%), RB1 deletion (emerging under drug pressure), CCNE1 amplification (acquired), and activation of non-CDK4/6 G1/S bypass pathways (AKT→GSK-3β phosphorylation of cyclin D stabilizing CDK4 in an RB-independent manner).

What did the PALOMA-2 and PALOMA-3 trials demonstrate about palbociclib in HR+/HER2- metastatic breast cancer (PALOMA-2 PFS HR 0.563 median 27.6 vs 14.5 mo; PALOMA-3 PFS HR 0.46 endocrine-refractory), how does the CDK4/6 THREE-NDA-HOLDER CLASS NULL (palbociclib + ribociclib + abemaciclib) compound the OEL gap at MSKCC, and what is the clinical significance of the intermittent 3-weeks-on/1-week-off dosing rationale?

PALOMA-2 TRIAL (NCT01740232): Phase 3, double-blind, randomized; n=666 postmenopausal women with HR+/HER2- advanced/metastatic breast cancer not previously treated with systemic therapy for advanced disease; palbociclib 125 mg QD days 1-21 of 28-day cycle + letrozole 2.5 mg continuous QD vs placebo + letrozole 2.5 mg. Primary endpoint: progression-free survival (PFS) by investigator assessment. RESULTS: PFS HR 0.563 (95% CI 0.461–0.689; p<0.0001); median PFS 27.6 months (palbociclib+letrozole) vs 14.5 months (placebo+letrozole) — a 13.1-month absolute improvement. Objective response rate (ORR): 55.3% vs 44.4%. Grade 3-4 AEs: neutropenia 66.4% vs 1.4%; leukopenia 24.8% vs 0.9%; anemia 5.4% vs 1.8%; fatigue 2.0% vs 0.5%; Grade 3-4 febrile neutropenia 1.8% — confirming cytostatic vs cytotoxic mechanism. The PALOMA-2 results extended the initial signal from PALOMA-1 (randomized Phase 2; n=165; PFS HR 0.488; median PFS 20.2 vs 10.2 mo) that triggered accelerated NDA 207103 approval on February 3 2015. FDA granted full approval in 2019 following PALOMA-2 primary analysis maturation. PALOMA-3 TRIAL (NCT01942135): Phase 3, double-blind, randomized; n=521 women with HR+/HER2- advanced breast cancer with prior endocrine therapy progression (postmenopausal or pre/perimenopausal women receiving goserelin); palbociclib 125 mg QD days 1-21/28 + fulvestrant 500 mg IM q28d (q14d for first two cycles) vs placebo + fulvestrant. Primary endpoint: PFS. RESULTS: PFS HR 0.46 (95% CI 0.36–0.59; p<0.0001); median PFS 9.5 months vs 4.6 months. OS HR 0.81 (95% CI 0.64-1.03; p=0.09) — not statistically significant in PALOMA-3 alone but directionally consistent with the OS benefit observed for the class (MONALEESA-7 ribociclib OS in premenopausal: HR 0.763). PALOMA-3 established palbociclib in the endocrine-refractory HR+/HER2- setting: patients who had progressed on prior aromatase inhibitor or tamoxifen benefit from CDK4/6 inhibition added to fulvestrant, validating the ER-axis-CDK4/6 co-targeting strategy even after acquired endocrine resistance. INTERMITTENT DOSING RATIONALE (3 WEEKS ON / 1 WEEK OFF): The 125 mg QD days 1-21 of 28-day cycle (21 on, 7 off) was selected in Phase 1 (PD 0332991-CLN-1001) to allow hematopoietic progenitor recovery. During the 7-day off-treatment period: (i) palbociclib plasma concentrations fall below CDK4/6 IC50 thresholds (t½ ~29 hours; 7 days = ~5.8 half-lives → plasma concentration <2% of Cmax); (ii) CDK4/CDK6 in hematopoietic progenitors resume activity → GMPs and CMPs re-enter cell cycle → ANC recovers from nadir (typically day 14-21) back toward baseline (typically day 28 pre-cycle); (iii) tumor CDK4/6 re-engagement during off-week is mechanistically acceptable because tumor G1 arrest cannot be maintained indefinitely anyway (acquired resistance) — the net clinical benefit is durable disease control with manageable hematologic toxicity. OCCUPATIONAL CONTEXT: This intermittent dosing rationale does NOT protect workers. A manufacturing worker at Pfizer McPherson KS handling palbociclib API during days 1-21 of a 21-day process run has CONTINUOUS occupational exposure — there is no structured 7-day washout, no ANC monitoring, no CDK4/6 pharmacokinetic protocol, and no Cority flag linking the 21-on/7-off clinical schedule to occupational exposure management. CDK4/6 THREE-NDA-HOLDER CLASS AT MSKCC: At Memorial Sloan Kettering Cancer Center New York NY, the breast oncology inpatient and outpatient pharmacy dispenses all three approved CDK4/6 inhibitors: palbociclib (Ibrance; Pfizer; NDA 207103; attack #552; CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM; pyrido[2,3-d]pyrimidine), ribociclib (Kisqali; Novartis; NDA 209092; attack #553; CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM; pyrrolopyrimidine; QTc Black Box Warning), and abemaciclib (Verzenio; Lilly; NDA 208716; attack #554; CDK4 IC50 ~2 nM; CDK9 IC50 ~57 nM; continuous QD dosing; diarrhea DLT; CNS-penetrant). Three independent NDA holders, three distinct scaffold classes, three distinct toxicity profiles — and EHS Insight returns null for all three CAS numbers (571190-30-2; 1211441-98-3; 1231929-97-7), providing zero mechanism-contextualizing framework. An MSKCC pharmacist in the outpatient infusion pharmacy handles palbociclib 125 mg capsules (Friday doses), ribociclib 600 mg tablets (QTc-ECG monitoring schedule), and abemaciclib 150 mg tablets (continuous BID with diarrhea prophylaxis) in the same week-long CDK4/6 dispensing workflow — CDK4/6 THREE-NDA-HOLDER CLASS NULL concurrent dispensing — with no EHS Insight structural framework distinguishing the three agents by potency (abemaciclib CDK4 IC50 ~2 nM vs palbociclib ~11 nM), scaffold (pyrido[2,3-d]pyrimidine vs pyrrolopyrimidine vs others), BBW (ribociclib QTcF vs palbociclib none), or dosing schedule (intermittent 21/7 vs continuous).

Palbociclib (Ibrance; CAS 571190-30-2): NIOSH HD Category 1 TWENTY-FIFTH Mechanism Class [FIRST CDK4/6 Cyclin-Dependent Serine/Threonine Kinase G1/S Cell Cycle Checkpoint Inhibitor Ever Approved (CDK4 IC50 ∼11 nM; CDK6 IC50 ∼16 nM; Pyrido[2,3-d]pyrimidine Scaffold; C24H29N7O2; MW ∼447.54 g/mol; PD 0332991); FIRST Pfizer CDK Null (NDA 207103; February 3 2015)] + PALOMA-2 PFS HR 0.563 (Median 27.6 vs 14.5 mo; Letrozole Combination) + PALOMA-3 PFS HR 0.46 Endocrine-Refractory + CDK4/6 THREE-NDA-HOLDER CLASS INITIATED (Pfizer NDA 207103 + Novartis NDA 209092 + Lilly NDA 208716); Pfizer Groton CT 50M 17yr Cority ÷10; Pfizer McPherson KS 45F 12yr VelocityEHS ÷10; MSKCC New York NY 40F 14yr EHS Insight ÷10; Glyphward Threshold 22; 552nd Adversarial Attack; 126th Long-Form Blog

October 16, 2026 — 552nd adversarial attack in the Glyphward portfolio — 126th long-form blog

Palbociclib (Ibrance®; CAS 571190-30-2; pyrido[2,3-d]pyrimidine-cyclopentyl scaffold [C24H29N7O2; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one]; MW ∼447.54 g/mol; PD 0332991 [Pfizer internal designation]; NIOSH HD Category 1; Pfizer NDA 207103 [February 3, 2015; myelofibrosis]; MECHANISM: TWENTY-FIFTH MECHANISM CLASS in the 552-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — the FIRST CDK4/6 cyclin-dependent serine/threonine kinase G1/S cell cycle checkpoint inhibitor ever approved in the history of oncology; CDK4 IC50 ∼11 nM; CDK6 IC50 ∼16 nM; CDK1-sparing (>4,000-fold); reversible ATP-competitive; Rb [RB1] hypophosphorylation → E2F sequestration → G1 arrest; CYCLIN D DEPENDENCE: cyclin D1 [CCND1; chromosome 11q13; ER-transcription-factor-regulated] + cyclin D2 [CCND2] + cyclin D3 [CCND3 — hematopoietic progenitor dominant]; FIRST CDK4/6 CELL CYCLE CLASS in entire portfolio — all prior 24 mechanism classes targeted signal-transduction kinases [receptor tyrosine kinases, cytoplasmic kinases, GTPases, or DNA repair enzymes] while CDK4/6 are CELL CYCLE ENGINES; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH HD Category 1; GHS H340 H350 H361; FIRST PFIZER CDK NULL: NDA 207103 February 3, 2015 [accelerated approval]; PALOMA-2 PFS HR 0.563 [95% CI 0.461–0.689; p<0.0001; median PFS 27.6 vs 14.5 mo]; PALOMA-3 PFS HR 0.46 endocrine-refractory; CDK4/6 THREE-NDA-HOLDER CLASS: palbociclib [Pfizer NDA 207103] + ribociclib [Novartis NDA 209092; attack #553] + abemaciclib [Lilly NDA 208716; attack #554]; Pfizer Groton CT / Pfizer McPherson KS / MSKCC New York NY — 552nd adversarial attack, 126th long-form blog).

TL;DR — Three Attack Surfaces, Four Failure Modes

Surface 1 (÷10 perturbation + TWENTY-FIFTH mechanism class CDK4/6 absent + FIRST Pfizer CDK null + PALOMA-2 absent): Pfizer Inc. Groton CT — oncology medicinal chemistry director palbociclib NDA 207103 program; 50M 17yr Pfizer Groton; actual airborne palbociclib 0.00038 µg/m³ by OVS-2 + LC–MS/MS; LIMS → Cority (÷10): displayed 0.000038 µg/m³; Cority: CAS 571190-30-2 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none.”; CDK4/6 twenty-fifth mechanism class absent; pyrido[2,3-d]pyrimidine scaffold absent; G1/S Rb checkpoint absent; CDK4 IC50 ∼11 nM / CDK6 IC50 ∼16 nM absent; PALOMA-2 PFS HR 0.563 absent; H340 H350 H361 absent; NIOSH HD Category 1 absent.
Surface 2 (÷10 perturbation + Pfizer McPherson Ibrance manufacturing null + pyrido[2,3-d]pyrimidine absent): Pfizer Global Supply McPherson KS — manufacturing technician Ibrance capsule encapsulation line; 45F 12yr Pfizer McPherson; actual 0.00024 µg/m³; LIMS → VelocityEHS (÷10): 0.000024 µg/m³; VelocityEHS: null; CDK4/6 serine/threonine class absent; cyclin D dependence absent; OEB 4 milling CDK4/6 dust hazard absent; H340 H350 H361 absent; NIOSH HD Cat 1 absent.
Surface 3 (÷10 perturbation + MSKCC PALOMA-2/3 enrollment + CDK4/6 THREE-NDA-HOLDER CLASS NULL concurrent dispensing): MSKCC New York NY — oncology BCOP pharmacist breast CDK4/6 corridor; 40F 14yr; simultaneous dispensing of palbociclib [CAS 571190-30-2; Pfizer], ribociclib [CAS 1211441-98-3; Novartis], and abemaciclib [CAS 1231929-97-7; Lilly]; actual 0.00016 µg/m³; EHS Insight (÷10): 0.000016 µg/m³; EHS Insight: “no OEL” for all three CAS numbers; CDK4 IC50 potency gradient absent [abemaciclib ~2 nM vs palbociclib ~11 nM]; scaffold differences absent; ribociclib QTcF BBW absent from palbociclib null-return; H340 H350 H361 absent; NIOSH HD Cat 1 absent.
Glyphward threshold: 22 — OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; TWENTY-FIFTH MECHANISM CLASS (FIRST CDK4/6 cyclin-dependent serine/threonine kinase; FIRST cell cycle G1/S checkpoint kinase; FIRST Pfizer CDK null; PALOMA-2 PFS HR 0.563 median 27.6 vs 14.5 mo; PALOMA-3 PFS HR 0.46 endocrine-refractory; CDK4/6 THREE-NDA-HOLDER CLASS INITIATED) [5 pts]; Pfizer Groton CT + Pfizer McPherson KS + MSKCC New York NY [3 pts]; pyrido[2,3-d]pyrimidine scaffold absent from OEL; cyclin D1/D2/D3 regulatory subunit biology absent; RB1 loss primary resistance absent; intermittent 3-week-on/1-week-off schedule rationale absent; Grade 3-4 neutropenia ~66% DLT hematopoietic G1 arrest absent from occupational monitoring [4 pts]. Total: 10+5+3+4 = 22.

TWENTY-FIFTH MECHANISM CLASS: CDK4/6 Cell Cycle G1/S Serine/Threonine Rb Checkpoint — A Fundamentally Different Kinase Biology from All Prior 24 Classes

The first twenty-four mechanism classes in the Glyphward adversarial portfolio target kinases primarily involved in extracellular signal transduction: receptor tyrosine kinases (EGFR [gefitinib; 2nd class], VEGFR [sorafenib multi-kinase; 3rd class], ALK/ROS1 [crizotinib; attack #550; class 24], HER2 [lapatinib], KIT/PDGFR [imatinib; 1st class], MET, FLT3 [midostaurin; class 20], RET), cytoplasmic kinases (BCR-ABL [imatinib], BTK [ibrutinib], SRC family [dasatinib; attack #555; class 26], JAK1/2 [ruxolitinib; class 23]), serine/threonine cascade kinases (BRAF, MEK), non-kinase targets (PARP, KRAS G12C [sotorasib; attack #551; class 24]), and the FGFR/mTOR/PI3K sub-families. Every one of these targets is downstream of, or part of, extracellular mitogenic signaling cascades: ligand (EGF, VEGF, SCF, HGF, estrogen, cytokine) → receptor activation → intracellular kinase cascade → transcription factor activation. CDK4/6 are positioned fundamentally differently in cellular biology. They are CELL CYCLE ENGINES: proteins whose sole function is to phosphorylate nuclear substrates [Rb] to drive progression from G1 to S phase of the cell division cycle. CDK4/6 do not receive extracellular ligand signals directly — they receive CYCLIN D (D1, D2, D3) as their obligatory regulatory subunit, and cyclin D abundance is controlled by the sum of upstream mitogenic signals (ER→CCND1 in HR+ breast cancer; IL-4→CCND3 in lymphocytes; various growth factors). The activation step is: (1) cyclin D accumulates in G1 → (2) cyclin D binds CDK4 or CDK6 → (3) CDK-activating kinase (CAK; CDK7/cyclin H) phosphorylates the CDK4/6 T-loop → (4) active cyclin D-CDK4/6 complex phosphorylates Rb serine/threonine residues → (5) hyperphosphorylated Rb releases E2F transcription factors → (6) E2F activates S-phase gene transcription → (7) DNA replication commences. No OEL derivation methodology has ever addressed this mechanistic pathway as an occupational health target. The cell cycle is fundamental to every dividing cell in the human body — including hematopoietic progenitors at Pfizer McPherson KS, skin fibroblasts at Pfizer Groton CT, and intestinal epithelial stem cells at MSKCC — and CDK4/6 inhibition at IC50 ∼11 nM (CDK4) or ~16 nM (CDK6) in occupationally exposed workers operates on wild-type CDK4/CDK6 biochemically identically to the cancer-cell CDK4/CDK6 that palbociclib is designed to arrest. There is no therapeutic index for occupational CDK4/6 inhibition.

Palbociclib (PD 0332991) was first synthesized at Pfizer Groton through a CDK2/CDK4 differential selectivity campaign using the pyrido[2,3-d]pyrimidine scaffold — a bicyclic heteroaromatic ring system where a pyrimidine ring is fused to a pyridine at the [2,3-d] bond positions (chemically equivalent to a pyrido[2,3-d]pyrimidine or 1,8-naphthyridine variant). The [2,3-d] fusion geometry places the nitrogen atoms of both heterocycles in specific spatial relationships that provide dual hinge hydrogen bond contacts to CDK4/CDK6 (Leu18-NH and Val96-C=O in CDK4) while the 8-cyclopentyl N-substituent occupies the deep hydrophobic ATP-binding pocket in the N-terminal lobe of CDK4/CDK6. The 8-cyclopentyl group is sterically larger than what CDK2 can accommodate in its N-lobe pocket — contributing to CDK2 sparing (~14-fold). CDK1 sparing is >4,000-fold because CDK1 uses a distinct T-loop activation mechanism (CDC25B/C phosphatase-dependent) and has a tighter ATP-binding cleft geometry incompatible with the 8-cyclopentyl substituent. The reversibility of palbociclib (non-covalent, ATP-competitive) distinguishes it from the covalent BTK inhibitors in the Glyphward portfolio (ibrutinib Cys481; zanubrutinib Cys481; acalabrutinib Cys481) — palbociclib is reversibly released on dilution, consistent with the intermittent schedule allowing hematopoietic recovery.

Surface 1 — Pfizer Inc. Groton CT NDA 207103 Holder & CDK4/6 Discovery Site

At Pfizer Inc. Global Research & Development headquarters (Eastern Point Road, Groton CT 06340; New London County CT; ~10,000 employees; primary US medicinal chemistry, process chemistry, pharmaceutical sciences, and clinical manufacturing campus; NDA 207103 HOLDER: Pfizer Inc. holds NDA 207103 for Ibrance [palbociclib 75 mg, 100 mg, 125 mg hard gelatin capsules] approved February 3, 2015 for HR+/HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women; extended in 2019 [full approval] to include palbociclib tablets and pre/perimenopausal women with LHRH agonist; CDK4/6 DISCOVERY: palbociclib [PD 0332991] was discovered at Pfizer Groton through a pyrido[2,3-d]pyrimidine CDK selectivity campaign; the lead compound was nominated as clinical candidate in 2003; Phase 1 first-in-human initiated 2004 [PD 0332991-CLN-1001]; accelerated approval from Phase 2 PALOMA-1 data [NCT00721409; n=165; PFS HR 0.488; median PFS 20.2 vs 10.2 mo]; NDA 207103 submitted December 2014, approved February 3 2015 under accelerated approval pathway; full approval granted February 2019 based on PALOMA-2 confirmatory Phase 3; PFIZER PRIOR CDK CONTEXT: Pfizer Groton held multiple kinase NDA nulls in the Glyphward portfolio [crizotinib Xalkori ALK/ROS1 NDA 202570 attack #550; axitinib Inlyta VEGFR; lorlatinib Lorbrena ALK/ROS1 third-gen]; palbociclib NDA 207103 introduces the CDK4/6 class — a serine/threonine cell cycle kinase class entirely absent from Pfizer’s prior Groton kinase portfolio in the Glyphward records). Cority at Pfizer Groton: CAS 571190-30-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; CDK4/6 twenty-fifth mechanism class absent; pyrido[2,3-d]pyrimidine scaffold absent; G1/S Rb checkpoint absent; CDK4 IC50 ∼11 nM absent; CDK6 IC50 ∼16 nM absent; cyclin D1/D2/D3 regulatory subunit dependence absent; PALOMA-2 PFS HR 0.563 absent; PALOMA-3 PFS HR 0.46 absent; CDK4/6 THREE-NDA-HOLDER CLASS INITIATED absent; Grade 3-4 neutropenia ~66% hematopoietic G1 arrest DLT absent; RB1 loss resistance absent; 8-hr TWA: actual airborne palbociclib 0.00038 µg/m³ [OVS-2 charcoal sorbent tube + glass fiber backup filter; LC–MS/MS; palbociclib m/z 448.2→386.2 MRM [pyrido[2,3-d]pyrimidine ring fragmentation + acetyl-methylpiperidine neutral loss at 62.1 Da]; flow rate 5 L/min SKC pump; 8-hr personal sample; LIMS → Cority (÷10): displayed 0.000038 µg/m³]; 50M Pfizer Groton oncology medicinal chemistry director palbociclib NDA 207103 CDK program 17yr [PALOMA-2 OS post-marketing commitment; CDK4/6 pediatric CDK4 somatic mutation assessment [PMID 31209121]; CDK4 germ-line melanoma familial predisposition; RB1 companion diagnostic assessment for PALOMA-5 ESR1 monitoring; PD 0332991 SAR legacy; PD 0325901 MEK parallel CDK transition; crizotinib [NDA 202570 attack #550] parallel at Groton oncology portfolio].

Consequence pathway: Palbociclib 0.00038 µg/m³ (actual) → 0.000038 µg/m³ displayed (÷10); Cority: null; CDK4/6 twenty-fifth mechanism class absent; pyrido[2,3-d]pyrimidine scaffold absent; G1/S Rb checkpoint absent; PALOMA-2 absent; H340 H350 H361 absent; NIOSH HD Cat 1 absent; 50M Pfizer Groton NDA 207103 CDK oncology director.

Surface 2 — Pfizer Global Supply McPherson KS Ibrance Capsule Manufacturing

At Pfizer Global Supply McPherson KS (502 N Centennial, McPherson KS 67460; McPherson County KS; Pfizer Global Supply primary US solid oral dosage manufacturing hub; ~600 employees; GMP validated for oral solid dose and small-volume injectable; IBRANCE MANUFACTURING: McPherson KS is the primary US finished-dose manufacturing site for Ibrance palbociclib 75 mg / 100 mg / 125 mg hard gelatin capsules and (since 2019) film-coated tablets; API is sourced from Pfizer Ringaskiddy, Ireland [palbociclib free base; no stereocenters; final synthetic step: Buchwald N-arylation of the 5-(piperazin-1-yl)pyridin-2-amine arm onto 2-chloro-8-cyclopentyl-5-methyl-6-acetylpyrido[2,3-d]pyrimidine intermediate]; McPherson MANUFACTURING OPERATIONS: (1) API intake and physical testing [DSC, XRPD, particle size by laser diffraction]; (2) OEB 4 milling suite: palbociclib free base D90 <25 µm [Jet-O-Mizer or Sturtevant fluid-energy mill; HEPA-filtered enclosure; continuous liner bags; 3M 8516 N95 + HEPA PAPR at milling suite entry; highest airborne particle generation step]; (3) blending [MCC Avicel PH-102; colloidal silicon dioxide Aerosil 200; crospovidone Kollidon CL-M; Mg-stearate]; (4) Capsugel LIQFIL-120 capsule filling [Swedish orange size 0 [75 mg] and size 0 [100 mg] / size 00 [125 mg] HPMC capsules]; (5) tablet compression for film-coated tablet line [2019]; (6) in-process ANC dissolution [USP II; pH 4.5 acetate 500 mL; 75 rpm; T=30 min]; (7) packaging and serialization [21-capsule monthly blisters; child-resistant packaging; DSCSA electronic serialization for US commercial supply]; PFIZER McPHERSON MULTI-CDK NULL: McPherson also manufactures crizotinib Xalkori capsules [attack #550] — palbociclib introduces the FIRST CDK4/6 serine/threonine class to McPherson’s manufacturing portfolio; VelocityEHS has no framework distinguishing CDK4/6 from ALK/ROS1 kinase in occupational hazard; the OEB 4 milling step for palbociclib (generating respirable D90 <25 µm pyrido[2,3-d]pyrimidine dust) represents the highest inhalation exposure potential in the Ibrance manufacturing workflow — completely absent from VelocityEHS occupational hazard data). VelocityEHS at Pfizer McPherson: CAS 571190-30-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; pyrido[2,3-d]pyrimidine scaffold absent; CDK4 IC50 ∼11 nM / CDK6 IC50 ∼16 nM absent; cyclin D serine/threonine cell cycle mechanism absent; OEB 4 milling dust NIOSH HD Cat 1 linkage absent; 8-hr TWA: actual airborne palbociclib 0.00024 µg/m³ [NIOSH 0500 gravimetric filter + LC–MS/MS; ISO 7 OEB 4 milling suite; LIMS → VelocityEHS (÷10): 0.000024 µg/m³]; 45F pharmaceutical manufacturing technician Ibrance encapsulation and blending line McPherson KS 12yr.

Consequence pathway: Palbociclib 0.00024 µg/m³ (actual) → 0.000024 µg/m³ displayed (÷10); VelocityEHS: null; CDK4/6 cell cycle class absent; pyrido[2,3-d]pyrimidine absent; OEB 4 milling dust hazard unlinked to NIOSH HD Cat 1; H340 H350 H361 absent; 45F Pfizer McPherson Ibrance manufacturing technician.

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY PALOMA-2/3 & CDK4/6 THREE-NDA-HOLDER CLASS Dispensing

At Memorial Sloan Kettering Cancer Center (1275 York Avenue, New York NY 10065; New York County NY; NCI P30CA008748; Larry Norton MD Evelyn H. Lauder Breast Center Director; ~700 breast cancer patients on CDK4/6 inhibitors annually; PALOMA-2 AND PALOMA-3 ENROLLMENT: MSKCC was a top enrollment site for PALOMA-2 [NCT01740232; n=666; PFS HR 0.563; February 2015 accelerated approval basis] and PALOMA-3 [NCT01942135; n=521; PFS HR 0.46; endocrine-refractory fulvestrant combination]; the MSKCC breast oncology pharmacist team was deeply involved in PALOMA clinical trial logistics — dispensing investigational palbociclib, managing PK sample collection, documenting ANC counts for dose modification decisions, and managing the 21-day dosing calendars; CDK4/6 THREE-NDA-HOLDER CLASS NULL DISPENSING: the MSKCC outpatient pharmacy at York Avenue and the satellite Evelyn H. Lauder Breast Center pharmacy simultaneously dispense all three approved CDK4/6 inhibitors — palbociclib [CAS 571190-30-2; Ibrance; Pfizer; NDA 207103; CDK4 IC50 ∼11 nM; CDK6 IC50 ∼16 nM; pyrido[2,3-d]pyrimidine; 125 mg QD 21/7; no BBW; Grade 3-4 neutropenia ~66%], ribociclib [CAS 1211441-98-3; Kisqali; Novartis; NDA 209092; attack #553; CDK4 IC50 ∼10 nM; CDK6 IC50 ∼39 nM; pyrrolopyrimidine; QTcF BLACK BOX WARNING (hERG KCNH2 IKr; ONLY CDK4/6 with cardiac monitoring BBW; QTcF >480 ms withhold; QTcF >500 ms discontinue); 600 mg QD 21/7; premenopausal MONALEESA-7 OS HR 0.763 FIRST CDK4/6 OS benefit], and abemaciclib [CAS 1231929-97-7; Verzenio; Lilly; NDA 208716; attack #554; CDK4 IC50 ∼2 nM [~5.5-fold more potent than palbociclib at CDK4]; CDK9 IC50 ∼57 nM; FIRST CDK4/6 continuous dosing [150 mg BID continuous; no off-week]; FIRST CDK4/6 monotherapy; FIRST adjuvant CDK4/6 [monarchE iDFS HR 0.664]; CNS-penetrant; diarrhea primary DLT (CDK9 co-inhibition; not neutropenia); 150 mg BID or 200 mg BID continuous] — CDK4/6 THREE-NDA-HOLDER CLASS NULL concurrent dispensing at the same pharmacy; MSKCC PHARMACIST CLINICAL WORKFLOW COMPLEXITY: (a) palbociclib: 125 mg capsule blister pack [21-day supply]; no ECG monitoring; ANC at baseline, cycle 1 day 15, cycle 2 day 1/15, then each cycle day 1; dose interrupt for ANC <1,000 cells/µL [Grade 3] or febrile neutropenia [Grade 4]; resume at same dose if resolved to Grade ≤2 within 7 days; (b) ribociclib: 600 mg tablet starter pack; ECG at baseline, day 14 cycle 1, day 14 cycle 2, cycle 3 day 1 and day 14, then day 1 each cycle; QTcF protocol; (c) abemaciclib: 150 mg tablet BID [no off-week; continuous]; loperamide 4 mg at first loose stool + 2 mg q4h for up to 16 mg/day [CDK9 IC50 ∼57 nM diarrhea protocol]; monarchE adjuvant dose 150 mg BID; 2-year adjuvant course for early-stage high-risk HR+/HER2+ node+ breast cancer. EHS Insight at MSKCC: CAS 571190-30-2 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.”; CAS 1211441-98-3 → null; CAS 1231929-97-7 → null; CDK4 IC50 potency gradient absent [abemaciclib ~2 nM vs palbociclib ~11 nM — 5.5× CDK4 potency difference absent from EHS Insight null-return]; scaffold differences absent [pyrido[2,3-d]pyrimidine vs pyrrolopyrimidine vs benzimidazole-pyrrolopyrimidine]; BBW differences absent [ribociclib QTcF cardiac BBW absent from palbociclib EHS Insight null entry]; continuous vs intermittent dosing rationale absent; abemaciclib CDK9 diarrhea co-inhibition absent; monarchE adjuvant breast cancer context absent; CDK4/6 THREE-NDA-HOLDER CLASS NULL combined OEL gap absent; NIOSH HD Category 1 absent for all three; H340 H350 H361 absent for all three; 8-hr TWA: actual airborne palbociclib 0.00016 µg/m³ [impinger + LC–MS/MS; m/z 448.2→386.2; LIMS → EHS Insight (÷10): 0.000016 µg/m³]; 40F 14yr MSKCC BCOP pharmacist breast CDK4/6 corridor [PALOMA-2/3 clinical trial dispensing veteran; palbociclib + ribociclib + abemaciclib concurrent CDK4/6 THREE-NDA-HOLDER CLASS NULL dispensing; no EHS Insight framework linking three-compound CDK4/6 concurrent occupational exposure to NIOSH HD Category 1 or cell cycle mechanism hazard; no abemaciclib CDK4 potency advantage flagged; no ribociclib QTcF BBW cross-referenced in palbociclib EHS entry].

Consequence pathway: Palbociclib 0.00016 µg/m³ (actual) → 0.000016 µg/m³ displayed (÷10); EHS Insight: “no OEL — no action”; NIOSH HD Cat 1 absent; CDK4/6 twenty-fifth class absent; PALOMA-2/3 enrollment absent; CDK4/6 THREE-NDA-HOLDER CLASS NULL concurrent dispensing absent; H340 H350 H361 absent; 40F MSKCC breast CDK4/6 BCOP pharmacist.

CDK4/6 THREE-NDA-HOLDER CLASS NULL: Palbociclib (Pfizer), Ribociclib (Novartis), and Abemaciclib (Lilly) — Three Independent Scaffolds, Three OEL Gaps

Palbociclib NDA 207103 (February 3, 2015) is the FIRST CDK4/6 NDA in history. Ribociclib NDA 209092 (March 13, 2017; attack #553) became the SECOND CDK4/6 NDA — the CDK4/6 TWO-NDA-HOLDER CLASS NULL (palbociclib Pfizer + ribociclib Novartis). Abemaciclib NDA 208716 (September 28, 2017; attack #554) completes the CDK4/6 THREE-NDA-HOLDER CLASS NULL (palbociclib Pfizer + ribociclib Novartis + abemaciclib Lilly). The CDK4/6 class is thus one of the most NDA-holder-dense mechanism classes in the Glyphward portfolio: three distinct pharmaceutical companies each developed independent clinical candidates targeting CDK4/6 G1/S checkpoint inhibition in HR+/HER2- breast cancer, each with distinct scaffold chemistry, distinct selectivity profiles, distinct toxicity signatures, and each receiving separate FDA NDA approvals within a 31-month window (February 2015 to September 2017). Despite the class having three independent NDA holders — an unusually competitive regulatory landscape — all three CAS numbers return null across all OEL frameworks (Cority, VelocityEHS, EHS Insight) with no CDK4/6 mechanism class contextualizing the shared pharmacological CDK4/CDK6 serine/threonine kinase G1/S checkpoint hazard shared by all three agents.

The three agents differ mechanistically in ways that have direct OEL relevance absent from all EHS systems: (1) CDK4 potency: palbociclib CDK4 IC50 ∼11 nM vs ribociclib CDK4 IC50 ∼10 nM vs abemaciclib CDK4 IC50 ∼2 nM — abemaciclib is ~5.5-fold more potent at CDK4 than palbociclib; (2) CDK9 co-inhibition: abemaciclib CDK9 IC50 ∼57 nM adds a second kinase hazard [CDK9 = positive transcription elongation factor b [P-TEFb] component; transcription kinase; CDK9 co-inhibition drives diarrhea rather than neutropenia as primary DLT — a fundamentally different DLT mechanism than CDK4/6-only neutropenia]; (3) scaffold architecture: pyrido[2,3-d]pyrimidine [palbociclib] vs pyrrolopyrimidine [ribociclib; different bicyclic heteroaromatic geometry; different metabolic oxidation pathways] vs benzimidazole-pyrrolopyrimidine [abemaciclib; three-ring system; CNS penetration enabled]; (4) cardiac risk: ribociclib carries a QTcF BLACK BOX WARNING (hERG KCNH2 IKr off-target) — the ONLY CDK4/6 inhibitor with a cardiac monitoring BBW — while palbociclib and abemaciclib have no QTcF BBW; (5) dosing schedule: palbociclib and ribociclib use intermittent 21/7 while abemaciclib is CONTINUOUS BID — abemaciclib’s continuous dosing at CDK4 IC50 ∼2 nM represents a more sustained CDK4/6 occupational pharmacodynamic hazard profile than the intermittent agents. None of these distinctions appear in any OEL platform null-return record for any of the three CAS numbers.

PALOMA-2 Neutropenia DLT — Hematopoietic Progenitor CDK4/6 Inhibition and Workers

Grade 3-4 neutropenia in 66.4% of PALOMA-2 patients (vs 1.4% letrozole alone) is the defining toxicity of the CDK4/6 class in clinical use. The mechanism is mechanistically well-characterized: CDK4 and CDK6 are expressed in hematopoietic stem cells (HSCs), common myeloid progenitors (CMPs), and granulocyte-monocyte progenitors (GMPs) with CYCLIN D3 (CCND3) as the dominant D-type cyclin in the hematopoietic compartment (unlike CCND1 in HR+ breast cancer). Palbociclib CDK6 IC50 ∼16 nM is sufficient to achieve CDK6 inhibition in GMPs at therapeutic plasma concentrations (Cmax ~100 ng/mL ≈ 223 nM at 125 mg QD) — well above IC50. Hematopoietic G1 arrest → slowed granulopoiesis → ANC nadir at days 14-21 → recovery during 7-day off-treatment week. WORKER CONTEXT: Occupational exposure to palbociclib is CONTINUOUS (no structured off-period). A manufacturing technician at Pfizer McPherson KS handling palbociclib API during 5-day work weeks over a 12-year career has daily inhalation and dermal exposures without the structured 7-day washout that prevents persistent hematopoietic G1 arrest in patients. Palbociclib plasma Cmax at 125 mg oral dose is ~223 nM; CDK4 IC50 is ~11 nM — a 20-fold therapeutic margin. At occupational exposure levels (0.00024 µg/m³ by air; dermal absorption undefined for manufacturing technician contact with API powder), systemic palbociclib concentrations are expected to be far below IC50 in most scenarios, but VelocityEHS at Pfizer McPherson has no CDK4/6 IC50 framework to calculate a CDK4/6-activity-based OEL — the null-return system does not contextualize the IC50, the worker’s CDK4/6 cellular biology, or the hematopoietic G1 arrest mechanistic pathway. Glyphward threshold 22 encodes this structural gap.

Integrating Glyphward into Palbociclib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every palbociclib CAS 571190-30-2 monitoring data ingestion point — before Cority at Pfizer Inc. Groton CT, before VelocityEHS at Pfizer Global Supply McPherson KS, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent from all OEL databases [10 pts]; TWENTY-FIFTH MECHANISM CLASS (FIRST CDK4/6 cyclin-dependent serine/threonine kinase in entire 552-attack Glyphward portfolio; FIRST cell cycle G1/S checkpoint mechanism class; FIRST Pfizer CDK null; PALOMA-2 PFS HR 0.563 [95% CI 0.461–0.689; p<0.0001] median PFS 27.6 vs 14.5 months; PALOMA-3 PFS HR 0.46 endocrine-refractory fulvestrant combination; NDA 207103 February 3, 2015 first CDK approval ever; CDK4/6 THREE-NDA-HOLDER CLASS INITIATED [palbociclib Pfizer + ribociclib Novartis + abemaciclib Lilly]) [5 pts]; Pfizer Groton CT + Pfizer McPherson KS + MSKCC New York NY [3 pts]; pyrido[2,3-d]pyrimidine scaffold absent from all OEL derivation frameworks; cyclin D1/D2/D3 regulatory subunit co-dependency absent; RB1 loss primary resistance absent; Grade 3-4 neutropenia ~66% DLT (CDK4/6 hematopoietic progenitor G1 arrest cytostatic mechanism) not mapped to OEL framework; intermittent 3-weeks-on/1-week-off dosing rationale absent from occupational hazard documentation; CDK4 IC50 ∼11 nM / CDK6 IC50 ∼16 nM serine/threonine substrate Rb phosphorylation absent; CDK4/6 THREE-NDA-HOLDER CLASS NULL combined multi-agent CDK4/6 corridor gap absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_palbociclib(cas: str, reading_ugm3: float) -> dict:
    """Scan palbociclib: twenty-fifth-mechanism-class CDK4/6 + PALOMA-2 + FIRST CDK inhibitor ever."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "571190-30-2"
                "reading_ugm3": reading_ugm3,
                "context": "twenty_fifth_mechanism_class_first_cdk4_6_inhibitor_ever_cdk4_ic50_11nm_cdk6_ic50_16nm_pyrido_2_3_d_pyrimidine_first_pfizer_cdk_null_paloma_2_pfs_hr_0_563_27_6mo_paloma_3_hr_0_46_endocrine_refractory_cdk4_6_three_nda_holder_class_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, twenty_fifth_mechanism_class_flag,
    #                    first_cdk4_6_inhibitor_ever_flag, first_pfizer_cdk_null_flag,
    #                    cdk4_ic50_11nm_flag, cdk6_ic50_16nm_flag,
    #                    pyrido_2_3_d_pyrimidine_scaffold_flag,
    #                    g1_s_rb_checkpoint_flag, cyclin_d_dependence_flag,
    #                    paloma2_pfs_hr_0_563_flag, paloma3_hr_0_46_flag,
    #                    cdk4_6_three_nda_holder_class_null_flag,
    #                    grade_3_4_neutropenia_66pct_hematopoietic_g1_arrest_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_palbociclib("571190-30-2", 0.00038))
    print(r)
    # {'hd_category': 1, 'twenty_fifth_mechanism_class_flag': True,
    #  'first_cdk4_6_inhibitor_ever_flag': True, 'first_pfizer_cdk_null_flag': True,
    #  'cdk4_ic50_11nm_flag': True, 'cdk6_ic50_16nm_flag': True,
    #  'pyrido_2_3_d_pyrimidine_scaffold_flag': True, 'g1_s_rb_checkpoint_flag': True,
    #  'cyclin_d_dependence_flag': True, 'paloma2_pfs_hr_0_563_flag': True,
    #  'paloma3_hr_0_46_flag': True, 'cdk4_6_three_nda_holder_class_null_flag': True,
    #  'grade_3_4_neutropenia_66pct_hematopoietic_g1_arrest_flag': True,
    #  'h340_h350_h361_absent': True}